HONOReform Foundation

Email

steve@honoreform.org

Phone

T: +1 402 7218690

Web

www.HONOReform.org

Address

415 East 23rd Street, Fremont, California AA United States of America
About HONOReform Foundation

HONOReform (Hepatitis Outbreaks' National Organization for Reform) began as a response to a tragedy. Evelyn McKnight and 98 other cancer patients in rural Fremont, Nebraska, were infected with hepatitis in 2001. The cause? Healthcare providers failed to follow injection safety practices when providing treatment.

Far from an isolated event, the Nebraska outbreak is one of 35 documented outbreaks in non-hospital settings in America between 1998-2008. Patients from all walks of life who were receiving care for multiple conditions in a wide variety of health care settings have been infected with bloodborne pathogens, including HCV (hepatitis C).

HONOReform is working at all levels – from local communities to Capitol Hill – to save lives by ensuring that fundamental injection safety practices are followed each and every time. The HONOReform mission is shaped by a three-pronged commitment to safety:

• Safety by Design through adoption of safe injection devices that are engineered to remove human error;

• Safety by Incentives to spur on faster adoption of infection control guidelines by healthcare professionals and administrators;

• Safety by Education and reeducation of healthcare workers regarding infection control – and empowerment of patients to ask questions and report concerns.

By building safeguards into the injection process, incentivizing health care providers at all levels to universally follow fundamental safety standards, and educating and reeducating providers, all patients will be protected all the time. To achieve this goal, HONOReform works with healthcare stakeholders – including elected leaders, public health officials, patients, providers and industry – to make sure lessons are learned, standard practices are followed and lives are saved.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close